Calls for papers
-
United Therapeutics has announced the FDA’s approval of its NDA for Tyvaso treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics licensed Treprostinil… Read more . . .
-
According to CyanVac subsidiary Blue Lake Biotechnology, the FDA has granted Fast Track designation for the company’s BLB-201 intranasal vaccine against respiratory syncytial virus (RSV) in children under 2 and adults over 60. The vaccine… Read more . . .
-
CDMO Lonza has announced that it is adding dry powder inhaler testing capabilities at its facility in Tampa, FL, USA for increased DPI development capacity. Lonza, which established a Center of Excellence for DPI particle… Read more . . .
-
According to Biohaven Pharmaceuticals, the FDA has accepted the company’s NDA for its zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the treatment of migraine and has set a PDUFA goal date… Read more . . .
-
Approximately 400 OINDP experts gathered in Orlando, FL, USA May 1-May 5 for the first in-person Respiratory Drug Delivery meeting since 2019, with another 75 attending virtually. RDD Online’s Richard Dalby welcomed delegates from 28… Read more . . .
-
SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary… Read more . . .
-
According to Moderna Therapeutics, the company used its annual “Science and Technology Day” to highlight its work on lipid nanoparticle (LNP) mRNA formulations, and CEO Stéphane Bancel made special note of the company’s advances in… Read more . . .
-
Aston University spin out Aston Particle Technologies (APT) has closed a £1 million funding round according to lead investor DSW Ventures. The funding will be used for scale up of APT’s isothermal dry particle coating… Read more . . .
-
Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant’s SP-101 inhaled adeno-associated… Read more . . .
-
Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland